Goldman Sachs’s Verve Therapeutics VERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16.7M | Buy |
1,482,642
+69,524
| +5% | +$781K | ﹤0.01% | 1898 |
|
|
2025
Q1 | $6.46M | Buy |
1,413,118
+671,939
| +91% | +$3.07M | ﹤0.01% | 2560 |
|
|
2024
Q4 | $4.18M | Sell |
741,179
-306,887
| -29% | -$1.73M | ﹤0.01% | 2984 |
|
|
2024
Q3 | $5.07M | Sell |
1,048,066
-240,183
| -19% | -$1.16M | ﹤0.01% | 2743 |
|
|
2024
Q2 | $6.29M | Buy |
1,288,249
+457,379
| +55% | +$2.23M | ﹤0.01% | 2450 |
|
|
2024
Q1 | $11M | Buy |
830,870
+357,254
| +75% | +$4.74M | ﹤0.01% | 1975 |
|
|
2023
Q4 | $6.6M | Buy |
473,616
+268,079
| +130% | +$3.74M | ﹤0.01% | 2392 |
|
|
2023
Q3 | $2.73M | Sell |
205,537
-61,541
| -23% | -$816K | ﹤0.01% | 2898 |
|
|
2023
Q2 | $5.01M | Buy |
267,078
+4,135
| +2% | +$77.5K | ﹤0.01% | 2567 |
|
|
2023
Q1 | $3.79M | Sell |
262,943
-131,291
| -33% | -$1.89M | ﹤0.01% | 2749 |
|
|
2022
Q4 | $7.63M | Buy |
394,234
+90,881
| +30% | +$1.76M | ﹤0.01% | 2324 |
|
|
2022
Q3 | $10.4M | Buy |
303,353
+228,594
| +306% | +$7.85M | ﹤0.01% | 2087 |
|
|
2022
Q2 | $1.14M | Sell |
74,759
-31,609
| -30% | -$483K | ﹤0.01% | 3851 |
|
|
2022
Q1 | $2.43M | Buy |
106,368
+53,968
| +103% | +$1.23M | ﹤0.01% | 3427 |
|
|
2021
Q4 | $1.93M | Buy |
52,400
+10,246
| +24% | +$378K | ﹤0.01% | 3528 |
|
|
2021
Q3 | $1.98M | Sell |
42,154
-76,359
| -64% | -$3.59M | ﹤0.01% | 3491 |
|
|
2021
Q2 | $7.14M | Buy |
+118,513
| New | +$7.14M | ﹤0.01% | 2522 |
|